Moderna
MRNA
#1665
Rank
NZ$21.19 B
Marketcap
NZ$54.24
Share price
5.02%
Change (1 day)
-24.92%
Change (1 year)
Moderna, Inc. is an American biotechnology company focused on the discovery and development of messenger RNA-based drugs.

Moderna (MRNA) - P/B ratio

P/B ratio as of December 2025 : 1.25

According to Moderna 's latest financial reports the company has a price-to-book ratio of 5.30383.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.

Moderna - P/B ratio (from 2018 to 2025)

P/B ratio by year

Year P/B ratio Change
2025-12-311.23-12.91%
2024-12-311.42-48.24%
2023-12-312.74-24.15%
2022-12-313.61-50.43%
2021-12-317.28-54.9%
2020-12-3116.1188.09%
2019-12-315.6070.78%
2018-12-313.28
2017-12-31N/A

P/B ratio for similar companies or competitors

Company P/B ratio P/B ratio differencediff. Country
Regulus Therapeutics
RGLS
8.18 553.82%๐Ÿ‡บ๐Ÿ‡ธ USA
Merck
MRK
4.73 277.77%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
-0.0229-101.83%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
221 17,551.01%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
5.79 362.51%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Arrowhead Pharmaceuticals
ARWR
17.8 1,318.64%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
6.36 408.14%๐Ÿ‡บ๐Ÿ‡ธ USA